Biogen Inc. (BIIB) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $178.96. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BIIB = $279.46 (+56.2% from the current price, the stock appears undervalued). Analyst consensus target is BIIB = $208 (+16% upside).
Valuation: BIIB trades at a trailing Price-to-Earnings (P/E) of 20.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.88.
Financials: revenue is $9.8B, -1.2%/yr average growth. Net income is $1.3B, growing at -14%/yr. Net profit margin is 13.2% (healthy). Gross margin is 70.5% (-7.1 pp trend).
Balance sheet: total debt is $6.9B against $18.3B equity (Debt-to-Equity (D/E) ratio 0.38, conservative). Current ratio is 2.68 (strong liquidity). Debt-to-assets is 23.6%. Total assets: $29.4B.
Analyst outlook: 25 / 48 analysts rate BIIB as buy (52%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 47/100 (Partial), Growth 15/100 (Fail), Past 100/100 (Pass), Health 83/100 (Pass), Moat 65/100 (Partial), Future 58/100 (Partial), Income 55/100 (Partial).
